Global Markets

Scan to download

Faster Financial News and Market Quotes

Download App
Invite

[Waters Corp. Sees Increased Demand In India For GLP-1 Drug Testing Equipment] U.s.-based Waters Corp, A Maker Of Medical Testing Equipment, Is Experiencing Increased Demand From Indian Drugmakers Racing To Develop Generic Versions Of Popular GLP-1 Weight-loss Drugs Like Semaglutide Ahead Of The Patent Expiry In India In 2026. With Local Drugmakers Including Biocon, Cipla, Dr. Reddy's And Lupin Actively Developing These Generics For The Potentially $150 Billion Global Market, Waters' India Unit, Which Contributes About 8% To Its Global Sales, Anticipates Double-digit Revenue Growth Percentage In India And Expects Specific Basis Point Contributions From Its Overall India Business And GLP-1 Testing Demand.

Quick Access to 7x24

Quick Access to More Editor-selected Real-time News

Exclusive video for free

FastBull project team is dedicated to create exclusive videos

Real-time Quotes

View more faster market quotes

More comprehensive macro data and economic indicators

Members have access to entire historical data, guests can only view the last 4 years

Member-only Database

Comprehensive forex, commodity, and equity market data